Biotechnology company, GamaMabs Pharma, has received orphan drug designation from the US Food and Drug Administration (FDA) for its lead compound GM102 to treat advanced ovarian cancers.
Ovarian cancer
GM102 is a monoclonal antibody targeting Anti-Müllerian Human Receptor II (AMHR2) for the treatment of cancers. It exerts its anti-tumour activity through macrophage engagement resulting in tumour phagocytosis. The first-in-human GM102 Phase Ia/Ib trial is ongoing in gynaecological cancers, with initial results expected in the first half of this year.
“We are delighted that our lead drug, GM102, has received orphan drug designation from the FDA,” said Isabelle Tabah Fisch, chief medical officer of GamaMabs. “GM102 belongs to a new generation of immunotherapies; it brings hope to this subgroup of patients with advanced ovarian cancers. We are committed to the rapid progress of the clinical development of GM102 and look forward to presenting the initial results from our clinical study.”
